RNA Editing Medicines: Ram Aiyar on The Long Run

Ram Aiyar is today’s guest on The Long Run.

Ram is the CEO of Cambridge, Mass.-based Korro Bio. The company is developing medicines that edit RNA, instead of DNA, which more people have heard about.

Ram Aiyar, CEO, Korro Bio

Previously, Ram co-founded Corvidia Therapeutics and served on the management team up through its $2.1 billion acquisition by Novo Nordisk. He’s had a long and interesting set of experiences in science, large pharma, venture capital, and startups.

In this conversation, we cover Ram’s career journey and how it’s led him to this moment when it’s possible to develop drugs that can precisely intervene with underlying disease processes, at the level of RNA, and be re-dosed conveniently for patients who may or may not be good candidates for a DNA-editing treatment of the future.  

Please join me and Ram Aiyar on The Long Run.